New research challenges the long-standing idea that hydrocephalus is mainly caused by poor absorption of cerebrospinal fluid. A team at Stony Brook Medicine suggests instead that the brain cannot absorb the pulsatile energy from the heartbeat. They say a brain system called the cerebral windkessel normally removes heartbeat pulses so blood flow in capillaries is smooth.
The researchers used an electrical circuit model to study how pulses move in CSF and how an obstruction can cause hydrocephalus. The condition can affect people of any age and has many causes, such as birth problems, bleeding, head injury, tumors, and a form in older adults. Treatment is usually surgery with a CSF shunt, but shunts often malfunction and need repeat operations.
Difficult words
- hydrocephalus — a condition with too much fluid in the brain
- cerebrospinal fluid — clear liquid that surrounds the brain and spine
- pulsatile — having a regular strong beat or pulse
- cerebral windkessel — brain system that reduces heartbeat pulses in blood
- capillary — very small blood vessel that connects arteries and veinscapillaries
- obstruction — something that blocks movement or flow
- shunt — a device that moves fluid to another placeshunts
- malfunction — to fail to work correctly or stop working
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Which causes of hydrocephalus are mentioned in the article?
- Why might people need repeat operations after a shunt is placed?
- How can a simple model help researchers study pulses in the brain and CSF?
Related articles
New device measures blood viscosity in real time
Researchers at the University of Missouri created a non-invasive device that monitors blood viscosity and density in real time using ultrasound and software. It can read blood without drawing samples and may help in diseases like sickle cell.
Antibody and EGFR–STAT1 pathway point to new fibrosis treatments
Researchers at Yale found a human antibody that blocks epiregulin and lowers fibrosis markers. They also show EGFR activates STAT1 in fibroblasts, suggesting two treatment paths: block epiregulin or target the EGFR–STAT1 pathway.